Published in Ocular Surface

TearCare®/SightSciences—The MGD Myth

This post is sponsored by TearCare
15 min read

Join Derek Cunningham, OD, FAAO and Marc Bloomenstein, OD, FAAO as they tackle several myths related to treating dry eye disease as well as the benefits of the TearCare® System.

As a chronic condition, dry eye disease (DED) creates a tremendous burden for both patients and the healthcare system, with associated costs of $3.84 billion.1 Patients feel the burden of DED as they face the need for frequent office visits and a variety of at-home regimens that may include scrubs, tears, warm compresses, and more.1 Doctors feel the burden of DED as they deal with unsatisfied patients, the need for frequent visits, contact lens dropouts, and delayed cataract or refractive surgeries.
“For us as doctors, it just becomes kind of unsatisfactory,” Dr. Bloomenstein said. “We start patients on treatments and we don't get the results they think they're supposed to get.”
Within DED dynamics, meibomian gland dysfunction (MGD) plays a critical role, since it is attributed to 86 percent of total DED cases.2
MGD can create a negative cascade of events, including:
  • Low production and abnormal meibum
  • Disruption of the tear film lipid layer and evaporative dry eye
  • Tear film instability and inflammation of the ocular surface
“Hence our patients can't wear their contacts as comfortably, their vision fluctuates, and more importantly, we see corneal damage and eventually poor refractive or cataract outcomes,” Bloomenstein said. “Meibomian gland health really is integral to all of the things we do as optometrists.”

Myth Busters: Uncovering the truth behind popular myths about dry eye.

As the “Myth Busters,” Bloomenstein said their goal was to “uncover some of the truth behind these popular myths about dry eye,” starting with what he believes is the number one myth—that DED is complex and difficult to treat.

Myth: DED is complex and can be difficult to treat.

Highlighting the body of literature describing DED as a complex and multifactorial disease—as well as the complicated algorithms recommended to treat it—Bloomenstein said it can be challenging for busy doctors to keep up. As a result, some practitioners decide they don’t have the time or the tools to tackle DED.
Citing the list of possible contributors to DED, he said it’s not possible to manage every single one of them. But the good news is that treating DED effectively can be achieved by addressing its two major problems: inflammation and obstruction.
“One of the things we know to be true is that when the meibomian glands are affected, we can have obstruction of those glands, which in turn can also create inflammation,” Bloomenstein explained. “We have both inflammatory issues as well as obstructive issues. I think if we break it down quite simply to managing inflammation and obstruction, then I think we can break down this myth.”

Myth: Advanced formula artificial tears reestablish homeostasis.

Dr. Cunningham said he thinks the next myth—the idea that advanced formulation artificial tears can reestablish homeostasis—originated in a historical perception of limited resources in eye care, as well as a limited understanding of the etiology of DED.
“No matter what the cause is (of DED), there's a pathophysiological problem in the structure of the eye itself, whether it be a specific component or whether it be mechanical,” he explained. “And the idea that simply flushing more fluid into a system is going to fix a cellular response or a poor cellular mechanism is just not going to happen.”
In the distant past—40-50 years ago—Cunningham said the perception was that “if we could simply just add more lubrication, we would be able to stabilize an eye that didn't have enough.”
However, as the understanding of DED has evolved, so has the understanding of the tear film.
“We know now that we have separate layers in the tear film, and it's not necessarily the deficiency of any one layer, it's the recipe of the three layers together and how much you need of each one,” he explained. “So if you're deficient in one, simply adding a whole bunch of the other won't necessarily stabilize the tear film, and it can actually have a negative effect.”
As a result, the goal is to have better tear film homeostasis, keeping in mind that:
  • Artificial tears lack the biologically active components found in natural tears
  • While lubrication is an important part of a multifactorial approach, the innate tear film has better quality than artificial tears
  • Natural lipids from meibomian glands result in better tear film homeostasis
“So in this case, tears are still a very valuable aspect of dry eye [treatment], but we don't use them as a primary therapy,” he said. “They are a subsequent therapy to whatever step we're taking to reestablish normal cell function.”

Myth: Topical anti-inflammatory pharmaceuticals “fix” MGD.

Cunningham described the next myth as being related to “topical anti-inflammatory pharmaceuticals and the traditional myth that they can fix meibomian gland disease.”
Citing the value of anti-inflammatories as a “hallmark of treatment” throughout all areas of medicine, he said they also have limitations, and it’s important to understand what they are.
“We love steroids, and we use a lot of them. But we understand where they start and where they end,” Cunningham explained. “And the end is to get a more manageable tissue or more manageable organ to deal with. That's really why we're using them.”
Although anti-inflammatories can provide symptom relief and be very effective initially, they aren’t effective in addressing obstruction of the gland and establishing long-term eye health.
“So in this case, the myth that the steroid itself is going to re-establish normal cell function within a blocked or occluded meibomian gland is just not going to happen,” he said. “It will control symptoms. And then from there we can move on to more efficient ways of clearing the meibomian gland and truly helping long-term dry eye in these patients.”

Myth: Obstruction is too difficult to treat.

Cunningham said the next myth, that obstruction is too difficult to treat, has roots in the fact that “none of us were ever educated in school on the idea of treating obstructions.”
However, referencing protocols in other medical fields, he said it’s recognized that an occlusion “simply is not going to fix itself.”
Although using warm compresses has been a popular approach to dealing with meibomian gland obstruction, several factors limit their effectiveness—such as the need to maintain a certain temperature and frequency of application.
Cunningham said research indicates there are critical factors regarding the use of heat to address meibomian gland obstruction effectively.
“You really need to have an internal heat within the gland for a specific amount of time. If you don't reach that temperature-specific amount of time, you are not going to adequately heat the meibum,” he explained. “And in order to do that, not only do you have to have that temperature inside the eyelid, but any contact you have with the external eyelid will typically have a limited effect because the vasculature in your eyelid is going to take a lot of that heat away.”
As a result, Cunningham said warm compresses have a limited effect, since “it's very hard to maintain that therapeutic temperature within the gland itself.”
Additionally, he described the role of keratinization in obstruction of the meibomian gland.
“Any significant length of inflammation will cause a keratinization over the orifice of the gland,” Cunningham explained. “These are little plaques. You can't see them under the slit lamp. They're invisible, they're clear, but if you take a little removal device, you'll actually be surprised at the almost fish-scale nature of the lid margin when you remove these things. Unless you remove these plaques, you have no chance of actually evacuating the contents of the gland.”
Having addressed some of the historical issues doctors faced in treating obstruction, Cunningham transitioned to “an innovation that's been developed to allow us to do this more effectively, the TearCare® System.”

The TearCare® System: A better way

The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
The TearCare® System includes single-use SmartLids™ that provide a universal fit; precise, consistent and intelligent heat; and a natural blink design—as well as a portable SmartHub™ that enables sensor-driven feedback designed to deliver safe and consistent heat.
Noting that his clinic was involved in one of the clinical trials that compared the TearCare® system to the LipiFlow® Thermal Pulsation system, Bloomenstein said he was impressed with the simplicity and portability of the device.
“The challenge I had, especially with the LipiFlow® system, was that it was bulky, self-contained, and we couldn't move it from lane to lane,” he explained. “We have three offices in the valley … so having something portable really appealed to me and to our practice.”
He also likes the fact that the TearCare® System enables such a comfortable patient experience and helps both providers and patients see immediate results.
“What's beautiful about the TearCare® System is that patients are sitting in a chair, they're reading their phones, they're blinking,” he said. “But then I sit them behind the slit lamp and I can actually watch the meibum coming out of the glands. I think there's an absolute psychological benefit to letting patients know that I can see what we're producing, that we're reaping the benefits of what they just did. I think patients really appreciate that.”
Cunningham also commented on the simplicity of the TearCare® System, saying he initially dismissed the technology because it actually seemed too simple.
“We have these really elaborate heavy systems and when I first saw this, I was struggling to understand how and where it would be better,” he explained.
However, while involved in blepharitis research and the use of intense pulsed light therapy, he started to understand the value of how the TearCare® System works.
“We were doing an initial FDA study in the U.S, and I had to start examining eyelids very, very closely. It really made me understand the nature of the eyelid margin itself and how prone it is to inflammation,” Cunningham said. “That got my head turning and understanding how important it was that the heat be very directed and not produce collateral damage.”
He said that key insight is what caused him to re-evaluate the TearCare® system, since the application of heat is so well-controlled.
“It provides heat just where I want it to the lumen of the meibomian gland itself at a very specific amount for a very specific amount of time and then allows me to physically see the contents, which is critically important,” Cunningham explained.
He also liked the fact that it complemented other therapies he was prescribing, “making them much more successful.”
“It played very well into many of the prescription therapies I was already using. They were almost synergistic,” he said. “It made my immunomodulators work a little bit better. It made my steroids act faster, and vice versa, the steroids made this device work better. I even found a significant place for it in and around our use of IPL with a lot of the IPL studies and research we were doing.”
Citing the challenges of getting patients to consistently and accurately comply with the therapies they’re prescribed, Bloomenstein said the TearCare® System allows him to know that “I'm getting something done,” and more importantly, that patients receive the benefits of his work.
Cunningham added how important it is to address the root cause of a problem like MGD instead of just treating the symptoms.
Like Bloomenstein, he said his clinic loves how portable the TearCare® System is and that the intelligent Smarthub™ provides heat control and temperature monitoring throughout the treatment. If something needs addressed, an alarm sounds, providing immediate notification.
“There are a lot of things I like about this device,” he said. “It kind of endeared me towards this treatment.”
Bloomenstein agreed, saying he thinks it makes him “a better doctor” since the treatment and monitoring are so precise.
He also described the value of using the Clearance Assistant™ tool for meibomian gland expression, which provides precise gland targeting and the real-time visualization from which both doctors and patients can benefit.
“This is something I feel is maybe lost a little bit in school,” he explained. “We didn't really learn how to do these things, but once you get your hands on it and you start doing it, it's really the simplicity of it that makes it nice.”
Both cited the substantial body of recent research demonstrating therapeutic improvement using the TearCare® System that’s been published in peer-reviewed journals.
Noting that he participated in the OLYMPIA study, he said this is where he “really saw the significant improvement” of using LipiFlow® versus the TearCare® System.
Bloomenstein also underscored the power of seeing the results first-hand—which is why he thinks it’s a great idea to request a demo.
“The reality is that once you actually see it, once you actually can touch it, it makes a huge difference,” he said.
And that myth that obstruction is too difficult to treat?
“Busted,” Bloomenstein proclaimed. “We can attest that it’s quite simple, and more importantly, we have a better way we can do it. That better way for both of us is the TearCare® System.”


  1. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30:379–387.
  2. Lemp MA, Crews LA, Bron AJ, et al. . Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–478.
Derek Cunningham, OD, FAAO
About Derek Cunningham, OD, FAAO

Derek Cunningham, OD, FAAO has conducted advanced research that covers a vast spectrum of eyecare and neuroscience including; dry eye treatments, glaucoma medications and surgeries, retinal disease, cataract and lasik surgeries, cosmetic treatments and products, vision enhancement, and sports vision. His innovative research has been presented at all major meetings ranging from the American Retinal society, the Academies of Ophthalmology and Optometry, to the American College of Sports Medicine. His research has been featured in many medical journals and showcased in publications such as Sports Illustrated and Forbes Magazine.

In addition to having been an associate professor at Texas Tech School of Medicine, Dr. Cunningham also held adjunct professor status at the Inter American University of Puerto Rico and the University of Waterloo, University of Houston, and the University of Incarnate Word.

Dr. Cunningham is an internationally recognized educator, having provided continuing education lectures to eye doctors throughout the world. He is also a Fellow of the American Academy of Optometry and is board certified by the American Board of Optometry. He is also the founding Chair of the Integrated Ophthalmic Task Force for the American Society of Cataract and Refractive Surgery.

Dr. Cunningham is the director of the Dry Eye Institute at Dell Laser Consultants (DLC) and is well-published in the areas of advanced dry eye treatments and facial aesthetics. He has presented to and educated leading ophthalmologists, corneal specialists, and optometrists in the United States and numerous countries around the world. Many of Dr. Cunningham’s dry eye protocols are being used by academic institutions around the country and his eye disease grading scales are even research standards in other countries.

Derek Cunningham, OD, FAAO
Damon Dierker, OD, FAAO
About Damon Dierker, OD, FAAO

Dr. Dierker is Director of Optometric Services at Eye Surgeons of Indiana, an adjunct faculty member at the Indiana University School of Optometry, and Immediate Past President of the Indiana Optometric Association. Dr. Dierker is the Co-Founder and Program Chair of Eyes On Dry Eye, the largest event for eyecare professionals in the industry. He has made significant contributions to raising awareness of dry eye and ocular surface disease in the eyecare community, including the development of Dry Eye Boot Camp and other content resources across dozens of publications.

Damon Dierker, OD, FAAO
Marc Bloomenstein, OD, FAAO
About Marc Bloomenstein, OD, FAAO

Dr. Marc R. Bloomenstein is a 1990 graduate of the University of California at Los Angeles with a degree in Biology. He received his optometric degree from the New England College of Optometry in 1994. After graduation, Dr. Bloomenstein finished a residency in secondary ophthalmic care at the Barnet Dulaney Eye Center in Phoenix, Arizona. He received his fellowship from the American Academy of Optometry in December, 1998 and is a founding member of the Optometric Council on Refractive Technology.

Currently, Dr. Bloomenstein is at the Schwartz Laser Eye Center. Aside from lecturing and publishing on numerous anterior segment and refractive topics, Dr. Bloomenstein is on the editorial board of Primary Care of Optometry and Contemporary Optometry. He served as the President of the Arizona Optometric Association, as well as an Optometric Advisor to STAAR Surgical and Medtronics Solan. Dr. Bloomenstein is the President of the Board of the Arizona Optometric Charitable Foundation.

Marc Bloomenstein, OD, FAAO